✦ LIBER ✦
Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes
✍ Scribed by Aronson, Ronnie; Gottlieb, Peter A.; Christiansen, Jens S.; Donner, Thomas W.; Bosi, Emanuele; Bode, Bruce W.; Pozzilli, Paolo
- Book ID
- 126975700
- Publisher
- American Diabetes Association
- Year
- 2014
- Tongue
- English
- Weight
- 737 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0149-5992
No coin nor oath required. For personal study only.